No Data
No Data
FDA Approves Mirum Pharma's Livmarli Tablet Formulation For Treatment Of Cholestatic Pruritus In Patients With Alagille Syndrome And Progressive Familial Intrahepatic Cholestasis
Express News | Mirum Pharmaceuticals Inc - Livmarli Tablets to Be Available in June
Express News | Mirum’s Livmarli Now FDA Approved in Tablet Formulation
Express News | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
J.P. Morgan Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Cuts Target Price to $53
Does Mirum Pharmaceuticals (NASDAQ:MIRM) Have A Healthy Balance Sheet?